Date: 2016-05-16
Type of information: Licensing agreement
Compound: gene therapy product candidates based on the NAV Technology Platform
Company: RegenXBiosciences (USA - MD) Biogen (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: development commercialisation licensing
Action mechanism: gene therapy. The NAV Technology Platform is an adeno-associated virus (AAV) gene delivery platform consisting of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
Disease: two undisclosed rare genetic vision disorders
Details: * On May 16, 2016, RegenXBiosciences announced an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV Technology Platform for the treatment of two rare genetic vision disorders. Under the terms of the agreement, RegenXBiosciences has granted Biogen an exclusive worldwide research license, with rights to sublicense, to RegenXBiosciences’s NAV AAV8 and AAV9 vectors for the development of gene therapy product candidates for the treatment of two rare genetic vision disorders in humans. Upon selection of a single vector for each indication, the research license will convert to a commercial license.
Financial terms: In return for these rights, RegenXBiosciences will receive an undisclosed upfront payment, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.
Latest news:
